Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FBIO 
Fortress Biotech Inc (FBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: FBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.04% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 102.06M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 2 | Beta 1.62 | 52 Weeks Range 1.33 - 3.97 | Updated Date 09/17/2025 |
52 Weeks Range 1.33 - 3.97 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -24.84% | Operating Margin (TTM) -222.22% |
Management Effectiveness
Return on Assets (TTM) -40.94% | Return on Equity (TTM) -784.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 96894802 | Price to Sales(TTM) 1.72 |
Enterprise Value 96894802 | Price to Sales(TTM) 1.72 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 29754800 | Shares Floating 22175920 |
Shares Outstanding 29754800 | Shares Floating 22175920 | ||
Percent Insiders 20.97 | Percent Institutions 16.67 |
Upturn AI SWOT
Fortress Biotech Inc
Company Overview
History and Background
Fortress Biotech Inc. was founded in 2006. It is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products.
Core Business Areas
- Pharmaceutical Products: Develops and commercializes prescription pharmaceutical products.
- Biotechnology: Focuses on the development of novel therapies.
- Partner Companies: Manages and provides financial and operational support to a portfolio of subsidiary companies, including Checkpoint Therapeutics, Avenue Therapeutics, and Cyprium Therapeutics.
Leadership and Structure
Lindsay A. Rosenwald, M.D., serves as Chairman, President, and Chief Executive Officer. The company has a board of directors and various management teams overseeing different business units and subsidiaries.
Top Products and Market Share
Key Offerings
- DURAVOL (levothyroxine sodium): An FDA-approved treatment for hypothyroidism. Market share data is difficult to ascertain due to the generic nature of levothyroxine. Competitors include generic manufacturers of levothyroxine and brand-name products like Synthroid (AbbVie).
- IVABRADINE: A selective I(f) channel inhibitor. Checkpoint Therapeutics holds rights to this drug. Market share is currently pending regulatory approval and launch. Competitors would be other medications for heart conditions, which are plentiful.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries are characterized by high research and development costs, regulatory hurdles, and competition from both large and small companies. Innovation and product development are key drivers.
Positioning
Fortress Biotech operates as a holding company with a focus on acquiring and developing niche pharmaceutical and biotechnology assets. Its competitive advantage lies in its diversified portfolio and operational efficiency.
Total Addressable Market (TAM)
The total addressable market for Fortress Biotech's combined portfolio of products and pipeline is multi-billion USD annually, spanning across various therapeutic areas. Fortress Biotech is positioned through its pipeline and currently marketed therapeutics. Estimating a precise TAM and Fortress' share is limited by available market data.
Upturn SWOT Analysis
Strengths
- Diversified portfolio of subsidiaries and product candidates
- Experienced management team
- Strategic partnerships
- Focus on acquiring undervalued assets
Weaknesses
- Reliance on subsidiaries for revenue generation
- High operating expenses
- Significant debt load
- Dependence on regulatory approvals
Opportunities
- Acquisition of additional undervalued assets
- Advancement of pipeline candidates through clinical trials
- Expansion into new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles and delays
- Competition from larger pharmaceutical companies
- Patent expirations
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
Competitive Landscape
Fortress Biotech is much smaller than its major competitors. It focuses on niche markets and acquired products. Its advantages are its operational structure, but has less bargaining power than the larger organizations.
Major Acquisitions
Avenue Therapeutics
- Year: 2016
- Acquisition Price (USD millions): 18.5
- Strategic Rationale: Acquired to develop intravenous tramadol for post-operative pain management.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, with periods of rapid expansion followed by periods of consolidation. Growth trends are dependent on the performance of its subsidiaries and product approvals.
Future Projections: Future growth projections are dependent on the successful development and commercialization of pipeline candidates and acquisition of new assets. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the advancement of pipeline candidates through clinical trials and strategic acquisitions of new assets.
Summary
Fortress Biotech is a biopharmaceutical company with a diversified portfolio of assets, but is struggling. Its success depends on its subsidiaries and product candidates. The company needs to closely manage its debt and navigate regulatory hurdles. The focus on undervalued assets could drive future growth if managed properly.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Market Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data and financial metrics may be estimates and subject to change. Real time data was not used.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortress Biotech Inc
Exchange NASDAQ | Headquaters Bay Harbor Islands, FL, United States | ||
IPO Launch date 2011-11-17 | Executive Chairman, President & CEO Dr. Lindsay Allan Rosenwald M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://www.fortressbiotech.com |
Full time employees 101 | Website https://www.fortressbiotech.com | ||
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.